-$0.28 Earnings Per Share Expected for MyoKardia (MYOK) This Quarter

Wall Street brokerages expect that MyoKardia (NASDAQ:MYOK) will announce ($0.28) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for MyoKardia’s earnings. The lowest EPS estimate is ($0.34) and the highest is ($0.17). MyoKardia posted earnings per share of ($0.37) during the same quarter last year, which would indicate a positive year over year growth rate of 24.3%. The company is scheduled to announce its next earnings report on Tuesday, May 8th.

According to Zacks, analysts expect that MyoKardia will report full year earnings of ($1.35) per share for the current year, with EPS estimates ranging from ($1.56) to ($1.08). For the next financial year, analysts anticipate that the business will report earnings of ($2.37) per share, with EPS estimates ranging from ($3.84) to ($1.04). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow MyoKardia.

How to Become a New Pot Stock Millionaire

MyoKardia (NASDAQ:MYOK) last released its quarterly earnings data on Thursday, March 8th. The biotechnology company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.20. MyoKardia had a negative net margin of 204.48% and a negative return on equity of 24.58%. The business had revenue of $5.60 million during the quarter, compared to analyst estimates of $5.63 million.



A number of research analysts have recently commented on MYOK shares. BidaskClub upgraded shares of MyoKardia from a “hold” rating to a “buy” rating in a research report on Saturday, February 17th. Zacks Investment Research lowered shares of MyoKardia from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. Credit Suisse Group restated an “outperform” rating and set a $60.00 price target on shares of MyoKardia in a research report on Thursday, January 18th. BMO Capital Markets boosted their price target on shares of MyoKardia from $65.00 to $83.00 and gave the company an “outperform” rating in a research report on Friday, March 9th. Finally, ValuEngine upgraded shares of MyoKardia from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $65.57.

In other news, insider Jake Bauer sold 5,000 shares of MyoKardia stock in a transaction on Wednesday, April 11th. The shares were sold at an average price of $50.00, for a total transaction of $250,000.00. Following the completion of the sale, the insider now directly owns 66,777 shares of the company’s stock, valued at approximately $3,338,850. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Anastasios Gianakakos sold 3,000 shares of MyoKardia stock in a transaction on Wednesday, April 4th. The stock was sold at an average price of $47.95, for a total transaction of $143,850.00. Following the sale, the insider now directly owns 77,390 shares of the company’s stock, valued at $3,710,850.50. The disclosure for this sale can be found here. Insiders have sold a total of 19,164 shares of company stock valued at $1,038,566 over the last 90 days. Company insiders own 33.40% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Eversept Partners LLC bought a new stake in shares of MyoKardia during the 4th quarter worth $2,105,000. Schwab Charles Investment Management Inc. lifted its holdings in shares of MyoKardia by 40.3% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 80,718 shares of the biotechnology company’s stock worth $3,459,000 after acquiring an additional 23,172 shares during the last quarter. Victory Capital Management Inc. lifted its holdings in shares of MyoKardia by 22.3% during the 4th quarter. Victory Capital Management Inc. now owns 47,715 shares of the biotechnology company’s stock worth $2,009,000 after acquiring an additional 8,700 shares during the last quarter. Hudson Bay Capital Management LP bought a new stake in shares of MyoKardia during the 4th quarter worth $1,263,000. Finally, Wells Fargo & Company MN lifted its holdings in shares of MyoKardia by 2,151.7% during the 3rd quarter. Wells Fargo & Company MN now owns 417,439 shares of the biotechnology company’s stock worth $17,887,000 after acquiring an additional 398,900 shares during the last quarter. 83.49% of the stock is owned by institutional investors.

MyoKardia stock opened at $49.75 on Monday. MyoKardia has a 1-year low of $10.80 and a 1-year high of $62.83. The company has a market capitalization of $1,787.20, a P/E ratio of -35.54 and a beta of 3.64.

TRADEMARK VIOLATION NOTICE: “-$0.28 Earnings Per Share Expected for MyoKardia (MYOK) This Quarter” was originally published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://dakotafinancialnews.com/2018/04/16/0-28-earnings-per-share-expected-for-myokardia-myok-this-quarter.html.

About MyoKardia

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Get a free copy of the Zacks research report on MyoKardia (MYOK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for MyoKardia (NASDAQ:MYOK)

Receive News & Ratings for MyoKardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply